Matoke Holdings Ltd. - Company Research Report

---

Company Overview

• Name: Matoke Holdings Ltd.

• Mission: “To create a range of Reactive Oxygen® delivery systems to become the first choice range for clinicians treating acute, surgical, and chronic wounds, to control potential or actual infections, biofilm if present, whilst positively driving wound repair.”

• Founded By: No information is available.

• Founded: No information is available.

• Key People:

• Guy Reynolds, Chief Executive Officer

• Will Wijnberg, Executive Director

• Andy Currie, Non-Executive Director

• Professor Peter Schmid, Medical Advisory Committee Chair

• Annette Callaghan, Head of Regulatory

• Caroline Currie, Head of Finance

• Headquarters: 2 Michaels Court, Hanney Road, Southmoor, Abingdon, OX13 5HR, United Kingdom.

• Number of Employees: No information is available.

• Revenue: No information is available.

• Known For: Matoke Holdings is known for Reactive Oxygen® technology, which is a breakthrough in managing acute, surgical, and chronic wound infections, particularly effective against antibiotic-resistant pathogens.

Products

• Reactive Oxygen®:

• Description: A breakthrough technology aimed at managing wound infections and facilitating wound healing, particularly effective against WHO-listed antibiotic-resistant bacteria.

• Key Features:

• Active against all WHO antibiotic-resistant crisis bacteria.

• Prevents and disrupts biofilm formations, significantly enhancing treatment effectiveness.

• Helps in reducing microbial loads, thereby removing wound healing barriers.

• SurgihoneyRO™:

• Description: A CE-marked medical device in gel format using bioengineered honey to deliver Reactive Oxygen Species (ROS).

• Key Features:

• Provides enhanced healing and potent antimicrobial action.

• Carefully engineered to ensure precise antimicrobial potency.

• RO-101®:

• Description: A synthetic gel format of the Reactive Oxygen® formula, intended to replicate the antimicrobial capabilities of SurgihoneyRO™.

• Key Features:

• Effective as a topical prophylactic product against Covid-19, with strong antiviral and antibacterial properties.

Recent Developments

• New Products and Features:

• Development of RO-101® spray form as a preventive measure against Covid-19, showcasing strong antiviral and antibacterial activity.

• Continuous development and refinement of the Reactive Oxygen® platform to address limitations of honey-based preparations with entirely synthetic formulations.

• Partnerships:

• Active collaboration with global healthcare companies to accelerate technology impact on global health issues.

• Strategic partnership with Alantra, a corporate finance partner, providing advisory services to promote further technological developments.

• Leadership Changes:

• Appointment of Guy Reynolds as CEO and Will Wijnberg as Executive Director, succeeding founder Ian Staples.

• Professor Peter Schmid has been appointed Chair of the Medical Advisory Committee to bolster clinical research programs.

• Research and Development Partnerships:

• Engaged with top clinicians and government bodies, including the Walter Reed Army Institute of Research and Public Health England, to support the emerging applications of Reactive Oxygen® technology.

Conclusion

Matoke Holdings Ltd. is leveraging its proprietary Reactive Oxygen® technology to become a leader in treating wound infections and antibiotic-resistant pathogens. With a focus on innovation, strategic partnerships, and research, Matoke Holdings is poised to address significant medical challenges and drive advancements in wound management.